Global InformationDonanemab information
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | Amyloid beta |
| Clinical data | |
| Other names | LY3002813 |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number |
|
| UNII |
|
| KEGG |
|
| Chemical and physical data | |
| Formula | C6452H10038N1708O2013S42 |
| Molar mass | 145087.70 |
Donanemab (USAN; development code LY3002813) is a biological drug in Phase III clinical trials to determine whether it slows the progression of early Alzheimer's disease. Donanemab has shown positive results in its first trials.[1][2] Donanemab was developed by Eli Lilly and Co. and is under clinical development as a possible treatment for Alzheimer's disease.[1][3] There is currently no approved cure or disease-modifying treatment for Alzheimer's disease except for lecanemab.
Donanemab, also known as N3pG, is an antibody produced in mice that targets an abnormal protein, amyloid beta (Aβ). Although the cause of Alzheimer's disease remains unknown, advances in understanding amyloid pathology have revealed a possible relationship between the quantity of amyloid plaques deposited in the brain and the development of Alzheimer's disease. Donanemab targets amyloid plaque, potentially reducing the excess protein which may be a factor in Alzheimer's disease.
- ^ a b Mintun MA, Lo AC, Duggan Evans C, et al. (May 2021). "Donanemab in Early Alzheimer's Disease". The New England Journal of Medicine. 384 (18): 1691–1704. doi:10.1056/NEJMoa2100708. PMID 33720637.
- ^ Sims JR, Zimmer JA, Evans CD, et al. (17 July 2023). "Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial". JAMA. 330 (6): 512–527. doi:10.1001/jama.2023.13239. PMC 10352931. PMID 37459141.
- ^ Long JM, Holtzman DM (October 2019). "Alzheimer Disease: An Update on Pathobiology and Treatment Strategies". Cell. 179 (2): 312–339. doi:10.1016/j.cell.2019.09.001. PMC 6778042. PMID 31564456.